<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02720445</url>
  </required_header>
  <id_info>
    <org_study_id>ATRI-002-NIC</org_study_id>
    <secondary_id>R01AG047992</secondary_id>
    <secondary_id>131918</secondary_id>
    <nct_id>NCT02720445</nct_id>
  </id_info>
  <brief_title>Memory Improvement Through Nicotine Dosing (MIND) Study</brief_title>
  <acronym>MIND</acronym>
  <official_title>Long-Term Nicotine Treatment of Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alzheimer's Therapeutic Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see if daily transdermal nicotine is able to produce a
      significant cognitive, clinical and functional improvement in participants with MCI. Neuronal
      nicotinic receptors have long been known to play a critical role in memory function in
      preclinical studies, with nicotine improving attention, learning, and memory function.

      The study will enroll 300 participants for a 2 year period. Participants will be randomized
      (50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day,
      or placebo skin patch.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline of the Conners Continuous Performance Task (CPT) to Month 25</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Mild Cognitive Impairment - Clinical Global Impression of Change (MCI-CGIC) to Month 25</measure>
    <time_frame>2 years</time_frame>
    <description>The MCI-CGIC is the MCI version of the clinician's global impression of change. In this trial it will measure change in the subject's condition between the baseline visit and subsequent visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Cogstate Brief Battery (CBB) to Month 25</measure>
    <time_frame>2 years</time_frame>
    <description>This battery will be used for the purpose of assessing the cognitive status of the subjects and will assist in documenting multiple domains of cognitive impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline in New York University (NYU) Paragraph Recall to Month 25</measure>
    <time_frame>2 years</time_frame>
    <description>This test measures immediate and delayed verbal recall of a brief story.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Dementia Rating Scale (CDR) - Sum of Boxes (SOB) to Month 25</measure>
    <time_frame>2 years</time_frame>
    <description>The is a clinical scale that rates the severity of dementia as absent, questionable, mild, moderate, or severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline in Geriatric Depression Scale (GDS) to Month 25</measure>
    <time_frame>2 years</time_frame>
    <description>This is a 30-item self-report assessment used to identify depression in the elderly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) to Month 25</measure>
    <time_frame>2 years</time_frame>
    <description>This scale is an inventory developed to assess functional performance in subjects with Alzheimer's disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Older Adult Self Report (OASR) / Older Adult Behavior Checklist (OABCL) to Month 25</measure>
    <time_frame>2 years</time_frame>
    <description>The OASR/OABCL is a general index of psychopathologic symptoms and signs that is specifically relevant to elderly individuals and is developmentally appropriate, covers a wide range of psychopathologic signs and symptoms, and functional measures. It allows multi-informant perspective (both patient and informant). The items are focused on common elderly emotional, functional, or medical problems. The OASR is completed by the subject and the companion OABCL is completed by the informant.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Baseline in Cerebral Spinal Fluid (CSF) Biomarkers to Month 25</measure>
    <time_frame>2 years</time_frame>
    <description>CSF will be performed in approximately 50 participants each</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline of Volumetric Magnetic Resonance Imaging (vMRI) to Month 25</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Nicotine Transdermal Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 participants will wear nicotine transdermal patches during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Patch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>150 participants will wear matching placebo patches during waking hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Transdermal Patch</intervention_name>
    <description>21mg Nicotine transdermal patches worn during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment.</description>
    <arm_group_label>Nicotine Transdermal Patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Patch</intervention_name>
    <description>Matching placebo patches worn during waking hours.</description>
    <arm_group_label>Placebo Patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must have a subjective memory concern as reported by subject, study partner,
             or clinician

          2. Abnormal memory function documented by scoring within the education adjusted ranges on
             the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory
             Scale - Revised:

               -  less than or equal to 11 for 16 or more years of education

               -  less than or equal to 9 for 8 - 15 years of education

               -  less than or equal to 6 for 0 - 7 years of education

          3. Mini-Mental State Exam score between 24 and 30, inclusive

          4. Clinical Dementia Rating (CDR) Global = 0.5. Memory Box score must be at least 0.5

          5. General cognition and functional performance sufficiently preserved such that a
             diagnosis of Alzheimer's disease dementia cannot be made by the site physician at the
             time of the screening visit

          6. Age 55-90 (inclusive)

          7. Stable permitted medications for 4 weeks or longer as specified in Section 6,
             including:

             â€¢ Memantine is allowable if stable for 12 weeks prior to screen

          8. No significant cerebrovascular disease: Modified Hachinski score of less than or equal
             to 4

          9. Geriatric Depression Scale score of less than or equal to 9

         10. Study Partner is available who has frequent contact with the subject (e.g. an average
             of 10 hours per week or more), and can accompany the subject to most visits to answer
             questions about the subject

         11. Adequate visual and auditory acuity to allow neuropsychological testing

         12. Good general health with no additional diseases/disorders expected to interfere with
             the study

         13. ECG without clinically significant abnormalities that would be expected to interfere
             with study participation

         14. Subject is not pregnant, lactating, or of childbearing potential (i.e. women must be
             two years post-menopausal or surgically sterile)

         15. Completed six grades of education or has a good work history

         16. Must speak English fluently

        Exclusion Criteria:

          1. Regular use of tobacco products within the past year, such as smoking (cigarettes,
             pipes, cigars, etc.) or use of other nicotine products (chewing tobacco, e-cigarettes,
             nicotine patches, gum, sprays, etc.).

          2. Any significant neurologic disease such as Alzheimer's disease dementia, Parkinson's
             disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus,
             brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma,
             multiple sclerosis, or history of significant head trauma followed by persistent
             neurologic deficits or known structural brain abnormalities.

          3. Major depression, bipolar disorder as described in DSM-V within the past 1 year or
             psychotic features, agitation or behavioral problems within 3 months, which could lead
             to difficulty complying with the protocol

          4. History of schizophrenia (DSM V criteria)

          5. History of alcohol or substance abuse or dependence within the past 2 years (DSM V
             criteria)

          6. Clinically significant or unstable medical condition, including uncontrolled
             hypertension, uncontrolled diabetes, or significant cardiac, pulmonary, renal,
             hepatic, endocrine, or other systemic disease in the opinion of the Investigator, may
             either put the subject at risk because of participation in the study, or influence the
             results, or the subject's ability to participate in the study.

          7. Has had a history within the last 5 years of a primary or recurrent malignant disease
             with the exception of non-melanoma skin cancers, resected cutaneous squamous cell
             carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ
             prostate cancer with normal prostate-specific antigen post-treatment

          8. Clinically significant abnormalities in B12 or TFTs (Thyroid Function Tests) that
             might interfere with the study. A low B12 is exclusionary, unless follow-up labs
             (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is not
             physiologically significant.

          9. Clinically significant abnormalities in screening laboratories or ECG.

         10. Residence in skilled nursing facility.

         11. Use of any excluded medication as described in the protocol, including:

               -  Use of cholinesterase inhibitors or centrally acting cholinergic drugs

               -  Use of any investigational drugs within 30 days or 5 half-lives, whichever is
                  longer, prior to screening.

         12. For CSF sub-study participants, a current blood clotting or bleeding disorder, or
             significantly abnormal PT or PTT (partial thromboplastin time) at screening

         13. For MRI sub-study participants, contraindications for MRI studies, including
             claustrophobia, the presence of metal (ferromagnetic) implants, or cardiac pacemaker.

         14. Patients whom the Site PI deems to be otherwise ineligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Aisen, MD</last_name>
    <role>Study Director</role>
    <affiliation>USC Alzheimer's Therapeutic Research Institute (ATRI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Newhouse, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ATRI Recruitment</last_name>
    <email>mind-participate@usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Perseverance Research Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85254</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandon McCravey</last_name>
      <phone>480-471-6132</phone>
      <email>bmccravey@prcresearcheducation.com</email>
    </contact>
    <investigator>
      <last_name>Feras Aldaoud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Arkansas Veterans HS</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kalpana Padala</last_name>
      <phone>501-257-2044</phone>
      <email>Kalpana.padala@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>USC Rancho Los Amigos</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Bughi</last_name>
      <phone>562-385-7463</phone>
      <email>stephanieb@ranchoresearch.org</email>
    </contact>
    <investigator>
      <last_name>Mindy Aisen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Syrentis Clinical Research</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Medina</last_name>
      <phone>714-542-3008</phone>
      <phone_ext>308</phone_ext>
      <email>MMedinaCRC@gmail.com</email>
    </contact>
    <investigator>
      <last_name>John Duffy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>200072145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Bassett</last_name>
      <phone>202-687-2352</phone>
      <email>mjb438@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Raymond Scott Turner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jetliza Lesmes</last_name>
      <phone>561-374-8461</phone>
      <phone_ext>110</phone_ext>
      <email>jlesmes@brainmattersresearch.com</email>
    </contact>
    <investigator>
      <last_name>Mark Brody, MD, CPI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Jewish Health Systems</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Suarez</last_name>
      <phone>305-514-8710</phone>
      <email>ESuarez@miamijewishhealth.org</email>
    </contact>
    <investigator>
      <last_name>Marc Agronin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Freund</last_name>
      <phone>208-955-9030</phone>
      <email>afreund@acr-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>606113010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Robson</last_name>
      <phone>312-503-5212</phone>
      <email>jordan.robson@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Ian Grant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Ekstam-Smith</last_name>
      <phone>319-353-5158</phone>
      <email>karen-ekstam@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Delwyn Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cypress Medical Research Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea Hines</last_name>
      <phone>316-440-7000</phone>
      <email>chelsea@prairiehealthwellness.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Acadia Hospital</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Chamberlain</last_name>
      <phone>207-973-7726</phone>
      <email>kmchamberlain@emhs.org.org</email>
    </contact>
    <investigator>
      <last_name>Clifford Singer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bronson Lakeview Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49079</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candace Moore</last_name>
      <phone>269-337-4324</phone>
      <email>Candace.Moore@med.wmich.edu</email>
    </contact>
    <investigator>
      <last_name>Nadeem Mirza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Advanced Medicine and Research</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justine Saavedra</last_name>
      <phone>505-272-5631</phone>
      <email>jlsaavedra@salud.unm.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Rosenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>100166055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Chen</last_name>
      <phone>212-263-5845</phone>
      <email>shannon.chen@nyumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>100296552</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Ardolino</last_name>
      <phone>212-241-0438</phone>
      <email>allison.ardolino@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Clara Li, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrative Clinical Trials</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana Netrebchuk</last_name>
      <phone>718-444-7774</phone>
      <phone_ext>117</phone_ext>
      <email>svetlana.netrebchuk@iclinicaltrials.net</email>
    </contact>
    <investigator>
      <last_name>Inna Yuryev-Golger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clavenda Canty</last_name>
      <phone>336-713-5885</phone>
      <email>clcanty@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Mia Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jade Svoboda</last_name>
      <phone>216-682-0320</phone>
      <phone_ext>236</phone_ext>
      <email>jade.svoboda@rapidmedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Toby Briskin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tulsa Clinical Research</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Parsons</last_name>
      <email>jparsons@tulsaclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Ralph Richter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>294011113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Lapp</last_name>
      <phone>843-724-2302</phone>
      <email>allison.lapp@rsfh.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meharry Medical College</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Ross</last_name>
      <phone>615-875-0955</phone>
      <email>sally.ross@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Meghan Riddle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Garrett</last_name>
      <phone>713-441-9484</phone>
      <email>jmgarrett@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Masdeu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice (Yanmin) Li</last_name>
      <phone>608-263-4290</phone>
      <email>ali@clinicaltrials.wisc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nia.nih.gov/alzheimers</url>
    <description>Alzheimer's Disease Education and Referral (ADEAR) Center. The ADEAR Center is a service of the National Institute on Aging (NIA).</description>
  </link>
  <link>
    <url>http://keck.usc.edu/atri/research/studies/</url>
    <description>Alzheimer's Therapeutic Research Institute (ATRI). ATRI is the Coordinating Center for the MIND study.</description>
  </link>
  <link>
    <url>http://mindstudy.org/</url>
    <description>MIND study public website</description>
  </link>
  <reference>
    <citation>Newhouse PA, Potter A, Corwin J, Lenox R. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology. 1994 Apr;10(2):93-107.</citation>
    <PMID>8024677</PMID>
  </reference>
  <reference>
    <citation>Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, Pfaff A, Wilkins H, Howard D, Levin ED. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. 2012 Jan 10;78(2):91-101. doi: 10.1212/WNL.0b013e31823efcbb.</citation>
    <PMID>22232050</PMID>
  </reference>
  <reference>
    <citation>Dumas J, Hancur-Bucci C, Naylor M, Sites C, Newhouse P. Estrogen treatment effects on anticholinergic-induced cognitive dysfunction in normal postmenopausal women. Neuropsychopharmacology. 2006 Sep;31(9):2065-78. Epub 2006 Feb 15.</citation>
    <PMID>16482084</PMID>
  </reference>
  <reference>
    <citation>Newhouse PA, Dumas J, Hancur-Bucci C, Naylor M, Sites CK, Benkelfat C, Young SN. Estrogen administration negatively alters mood following monoaminergic depletion and psychosocial stress in postmenopausal women. Neuropsychopharmacology. 2008 Jun;33(7):1514-27. Epub 2007 Aug 15.</citation>
    <PMID>17700646</PMID>
  </reference>
  <reference>
    <citation>Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A, Murphy DL. Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology (Berl). 1988;95(2):171-5.</citation>
    <PMID>3137593</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2016</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Paul Aisen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Transdermal Patch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

